Daiichi Sankyo Company, Limited
Q1 FY2026 Earnings Results | Revenue approximately ¥2.3 trillion (YoY +21.1%)
Daiichi Sankyo's Q1 FY2026 earnings show revenue of approximately ¥2.3 trillion, a +21.1% YoY increase, with operating income rising to approximately ¥851 billion, indicating revenue growth and improved profitability.
Key Figures
- Revenue: approximately ¥2.3 trillion (YoY+21.1%)
- Operating Income: approximately ¥851 billion (YoY+47%)
- Net Income: approximately ¥686 billion (YoY-19.7%)
AI要約
Performance Overview
Daiichi Sankyo's Q1 FY2026 earnings show revenue of approximately ¥2.3 trillion, marking a 21.1% increase YoY. The growth was mainly driven by strong sales of pharmaceuticals such as Ehaerts® and Datrove® products. Although net income decreased to approximately ¥686 billion, a 19.7% YoY decline, operating income increased significantly by 47% to approximately ¥851 billion.
Future Outlook and Impact on Investors
The company will continue to focus on expanding new drug sales and enhancing the profitability of existing drugs to sustain revenue growth. Despite a temporary drop in net income due to fluctuations in exchange rates and increased R&D expenses, profitability is expected to improve over the medium to long term. For investors, the key attractions are ongoing revenue growth and expanding operating profit.
Revenue Trend
Operating Income Trend
Net Income Trend
Daiichi Sankyo Company Limited
Company overview · Stock price · Financial data · All IR
